Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05316597 · ClinicalTrials.gov registry record · NA
Do Terpenes Play a Role in the Stress-reducing Effects of a Forest Bathing Intervention?
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT05316597: Completed NA study, sponsored by University of Washington.
NCT05316597 is a NA study that has completed, run by University of Washington. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05316597, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
This pilot study evaluates the role terpenes play in the stress-reducing effects of a forest bathing intervention. Participants will participate in two interventions in random order: 1) terpene exposure and 2) no terpene exposure.
Primary Outcome
Assess whether VOC inhalation regulates psychophysiological outcomes of the terpenes-on vs. terpenes-off sessions. Ln High Frequency Heart Rate Variability at T2 (20 minutes into duration of exposure for each session)
Interventions
- BEHAVIORAL Forest bathing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2023-09-21 |
| Phase | NA |
What the finished NCT05316597 record still lists
NCT05316597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Forest bathing is the first listed.
NCT05316597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05316597 about?
NCT05316597 is a clinical study titled "Do Terpenes Play a Role in the Stress-reducing Effects of a Forest Bathing Intervention?". This pilot study evaluates the role terpenes play in the stress-reducing effects of a forest bathing intervention. Participants will participate in two interventions in random order: 1) terpene exposure and 2) no terpene exposure.
What is the current status of trial NCT05316597?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2022-07-12. Estimated completion is 2023-09-21.
What interventions are being tested in trial NCT05316597?
The interventions under investigation include: Forest bathing (BEHAVIORAL).
Who is sponsoring clinical trial NCT05316597?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05316597's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI